Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $78.00.

Several research firms have issued reports on VERA. The Goldman Sachs Group restated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, HC Wainwright increased their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total value of $701,705.00. Following the sale, the chief executive officer directly owned 198,244 shares of the company’s stock, valued at $7,519,394.92. This trade represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,951 shares of company stock valued at $2,392,387 over the last quarter. Company insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics during the second quarter valued at about $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics during the fourth quarter valued at about $71,000. Finally, Tower Research Capital LLC TRC raised its position in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 1.6%

Shares of Vera Therapeutics stock opened at $43.15 on Tuesday. Vera Therapeutics has a 52-week low of $19.07 and a 52-week high of $56.05. The stock’s 50-day simple moving average is $36.08 and its 200 day simple moving average is $41.44. The stock has a market capitalization of $3.10 billion, a P/E ratio of -7.79 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the company posted ($0.81) earnings per share. As a group, research analysts anticipate that Vera Therapeutics will post -6.23 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.